By clicking "Allow," you will be taken to a website that is independent of ViiV Healthcare. The site you linking to is not controlled or endorsed by ViiV Healthcare, and ViiV Healthcare is not responsible for the content provided on that site.
This site is exclusively for healthcare professionals in the US. It contains medical information about ViiV Healthcare medications.
It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
Efficacy and safety of long-acting cabotegravir + rilpivirine in participants with HIV/HCV co-infection: ATLAS-2M 48-week results. Presented at IDWeek 2021, September 29 - October 3, 2021, Virtual Conference. Poster Presentation.
Qualitative patient-participant perspectives on implementation of cabotegravir and rilpivirine long acting (CAB+RPV LA) injectable in the US (CUSTOMIZE). Presented at IDWeek 2021, September 29 - October 3, 2021, Virtual Conference. Poster Presentation.
Neonatal outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials. Presented at IDWeek 2021, September 29 - October 3, 2021, Virtual Conference. Poster Presentation.
Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting every 8 weeks to Bictegravir/ Emtricitabine/ Tenofovir alafenamide in Suppressed HIV-1 Infected Persons. Presented at IDWeek 2021, September 29 - October 3, 2021, Virtual Conference.
North American phase III experience with long-acting cabotegravir and rilpivirine: efficacy, safety and virologic outcomes. Presented at IDWeek 2021, September 29 - October 3, 2021, Virtual Conference. Poster Presentation.
Efficacy and tolerability of DTG+3TC in clinical practice: evidence from real world data. Presented at IDWeek 2021, September 29 - October 3, 2021, Virtual Conference. Poster Presentation.
Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 144 weeks (TANGO study). Presented at IDWeek 2021, September 29 - October 3, 2021, Virtual Conference. Poster Presentation.
The impact of the COVID-19 pandemic on clinical follow-up, monitoring and regimen discontinuation for people living with HIV in the US. Presented at IDWeek 2021, September 29 - October 3, 2021, Virtual Conference. Poster Presentation.
High rates of virologic suppression with DTG/3TC in newly diagnosed adults with HIV-1 infection and baseline viral load >500,000 c/mL: 48-week subgroup analysis of the STAT study. Presented at IDWeek 2021, September 29 - October 3, 2021, Virtual Conference. Oral Presentation.
Dolutegravir (DTG) use during pregnancy and birth outcomes: the antiretroviral pregnancy registry (APR). Presented at IDWeek 2021, September 29 - October 3, 2021, Virtual Conference. Oral Presentation.
Effects of the “undetectable = untransmittable” (“U=U”) educational campaign on treatment outcomes and perceptions among people living with HIV in North American countries. Presented at IDWeek 2021, September 29 - October 3, 2021, Virtual Conference. Oral Presentation.
Real-world persistency of patients receiving tenofovir-based pre-exposure prophylaxis for the prevention of HIV infection in the US. Presented at IDWeek 2021, September 29 - October 3, 2021, Virtual Conference. Poster Presentation.
This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.
My MSL
Enter zip code to find your MSL contact.
This site uses cookies and similar technologies (collectively, "cookies") to enhance your website experience and track the site's performance. These cookies are automatically enabled. By using this site, you agree to our use of these cookies in accordance with our Privacy Notice. Click on Privacy Choices below to manage your preferences, including to opt out of the sale or sharing of your information.
Managing Privacy Options
OPT OUT OF SALE AND SHARING OF INFORMATION
Your state law may allow you the right to opt out of the sale or sharing of your personal information for targeted advertising. You may opt out of such sale or share via the toggle available to you for "Targeting Cookies," and selecting the "Confirm my choices” button below. To limit sale or sharing of your information for targeting advertising offline, please see the "Cookies and Targeted Advertising Choices," section in the Privacy Notice and submit the required form.
Always Active
Necessary for the website to function appropriately, such as to store session data during a website visit, to manage cookie and tag preferences, and to protect the security of the website. In addition, some of these cookies are set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms.
Always Active
Enable the website to provide enhanced functionality and personalization, such as by helping us to measure how many visitors come to our websites, what sites our website visitors come from, and how often certain pages on our website are viewed. These cookies may be set by us or by third party providers, like our analytics service providers, whose services we have added to our pages.
Allow us to target and re-target you with relevant advertising. We and our advertising partners use information collected through these technologies to infer your interests in order to serve you more relevant advertisements on other sites. If you don’t allow these cookies, you will receive advertising, but it may be less relevant to you.
